Healthcare provider profile · identity verified

Ryan Burmeister

Internal Medicine · GRAND RAPIDS, MI · NPI 1922450246

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	546	176
Amlodipine Besylate	Amlodipine Besylate	333	103
Lisinopril	Lisinopril	285	89
Levothyroxine Sodium	Levothyroxine Sodium	275	84
Omeprazole	Omeprazole	241	76
Gabapentin	Gabapentin	207	50
Metoprolol Succinate	Metoprolol Succinate	195	63
Hydrochlorothiazide	Hydrochlorothiazide	157	51
Losartan Potassium	Losartan Potassium	152	50
Metformin Hcl	Metformin Hcl	142	42
Albuterol Sulfate Hfa	Albuterol Sulfate	137	27
Tamsulosin Hcl	Tamsulosin Hcl	127	35
Sertraline Hcl	Sertraline Hcl	117	37
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	115	27
Pravastatin Sodium	Pravastatin Sodium	112	32
Fluticasone Propionate	Fluticasone Propionate	103	37
Trazodone Hcl	Trazodone Hcl	102	33
Furosemide	Furosemide	98	37
Atenolol	Atenolol	95	28
Eliquis	Apixaban	91	29
Montelukast Sodium	Montelukast Sodium	88	31
Rosuvastatin Calcium	Rosuvastatin Calcium	87	32
Tramadol Hcl	Tramadol Hcl	86	22
Pregabalin	Pregabalin	80	15
Clonazepam	Clonazepam	76	suppressed
Xarelto	Rivaroxaban	76	18
Allopurinol	Allopurinol	75	20
Alprazolam	Alprazolam	67	13
Simvastatin	Simvastatin	66	19
Pantoprazole Sodium	Pantoprazole Sodium	64	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	21
Meloxicam	Meloxicam	60	19
Metformin Hcl Er	Metformin Hcl	54	15
Metoprolol Tartrate	Metoprolol Tartrate	54	19
Prednisone	Prednisone	52	26
Venlafaxine Hcl Er	Venlafaxine Hcl	51	13
Alendronate Sodium	Alendronate Sodium	50	18
Citalopram Hbr	Citalopram Hydrobromide	50	15
Duloxetine Hcl	Duloxetine Hcl	49	18
Potassium Chloride	Potassium Chloride	49	14
Fluoxetine Hcl	Fluoxetine Hcl	47	11
Zolpidem Tartrate	Zolpidem Tartrate	45	suppressed
Topiramate	Topiramate	43	14
Bupropion Xl	Bupropion Hcl	42	13
Carvedilol	Carvedilol	42	15
Lovastatin	Lovastatin	42	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	41	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	12
Trulicity	Dulaglutide	39	suppressed
Finasteride	Finasteride	38	suppressed
Jardiance	Empagliflozin	38	15
Clonidine Hcl	Clonidine Hcl	37	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	37	13
Diazepam	Diazepam	36	suppressed
Methocarbamol	Methocarbamol	36	16
Pioglitazone Hcl	Pioglitazone Hcl	35	suppressed
Morphine Sulfate Er	Morphine Sulfate	34	suppressed
Lorazepam	Lorazepam	32	11
Naproxen	Naproxen	32	suppressed
Methylprednisolone	Methylprednisolone	31	30
Valsartan	Valsartan	31	suppressed
Ezetimibe	Ezetimibe	30	11
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	29	suppressed
Azithromycin	Azithromycin	28	23
Clopidogrel	Clopidogrel Bisulfate	28	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Terazosin Hcl	Terazosin Hcl	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	21
Oxycodone Hcl	Oxycodone Hcl	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Glipizide	Glipizide	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Cephalexin	Cephalexin	22	19
Farxiga	Dapagliflozin Propanediol	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	16
Sildenafil Citrate	Sildenafil Citrate	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Famotidine	Famotidine	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Celecoxib	Celecoxib	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Estradiol	Estradiol	18	suppressed
Latanoprost	Latanoprost	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	16
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Ozempic	Semaglutide	12	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Risperidone	Risperidone	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error